Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study


Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Related Content